StackItSmart

Compound reference

Selank

Peptides2 cited findingsClinical review: not reviewed

Safety findings

Regulatory recordSupporting passage inspected

FDA's bulk drug substance safety review lists Selank acetate (also known as TP-7) as a withdrawn compounding nomination. FDA states it lacks important safety information for selank acetate administered to humans and is concerned about immunogenicity related to aggregation and peptide-related impurities for certain routes.[2]

  • An evidence gap identified by a regulator is not proof of either safety or harm.
  • This regulator source does not itself supply human outcome data for selank; see the separate small comparative clinical study record for that.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· New source relationship identified and added in the peptide-misc batch on 2026-09-09 while rereading the FDA bulk-safety page; proposed addition awaits independent editorial review.

Clinical & experimental findings

Human observational studyAbstract inspected

A small comparative study in patients with anxiety disorders reported symptom changes with Selank and medazepam. The abstract’s limited methods do not establish a robust effect estimate, healthy-person cognitive enhancement or freedom from dependence.[1]

  • Population, formulation and study-design uncertainty restrict applicability.
  • PubMed's own indexing tags this record as a randomized controlled trial, but the abstract text itself does not describe the randomization or blinding procedure used; it is treated here as an uncontrolled comparative report.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.

· Freshly reread the abstract via NCBI E-utilities; confirmed sample sizes (30/32) and flagged the indexing-vs-abstract-description discrepancy. No qualified clinical review.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Retained the limited comparative patient study and explicitly recorded missing allocation/masking/formulation detail.

  • High-quality clinical estimates, dependence outcomes, healthy cognition and kinetics remain unverified.
  • Other inherited assertions not supported by the published claim set remain unverified; no qualified clinician review has occurred.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

  1. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].

    2008. PMID:18454096 Abstract only.

    Inspected location: Abstract: methods and results

    Study context and inspection record
  2. FDA: Certain bulk drug substances for compounding that may present significant safety risks

    US Food and Drug Administration. FDA web page. The footer states "Content current as of: 04/22/2026" (22 April 2026), independently verified on 2026-09-09 by two separate fetch methods. The ibutamoren mesylate row's own dated actions remain the applicable dates for that row's content. 2026-04-22. Regulatory document.

    Inspected location: Ibutamoren mesylate row of the 503A/503B category-2 bulk-substances table: congestive-heart-failure safety-risk description and the row's own dated entries (503A added September 29, 2023; 503B added December 29, 2022). Also inspected for this batch: the category-2 table row for kisspeptin-10, and the withdrawn-nomination rows for BPC-157, cathelicidin LL-37, emideltide (DSIP), epitalon, GHK-Cu, melanotan II, MOTs-C, selank acetate (TP-7), semax (heptapeptide) and thymosin alpha-1; and the earlier named GHRP-6, PEG-MGF, GHK-Cu and GHRP-2 rows

    Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts
  • peptide-pmid-18454096: Abstract: methods and results

View this compound in the research library →

Related records in this class

Grouped under Peptides for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.

StackItSmart

Age confirmation

This reference discusses steroids, SARMs and other compounds. It is educational, not medical advice, and does not recommend using or combining them.

Your confirmation is saved in this browser when storage is available.